NEW CME WEBCAST PROGRAM
Release Date: July 15, 2008
Expiration Date: July 15, 2009
Program Overview 

This presidential-style debate, featuring 2 nationally known speakers and a local moderator, will explore whether to change or stay the course with ARV therapy in a patient with an HIV RNA <50 c/mL. Included in the debate will be a discussion of recent data, including those from the 15th CROI, which indicate the potential positive and negative effects of changing ARV therapy in a fully suppressed patient. This program is for health care providers who treat HIV-positive patients and there are no prerequisites.


Learning Objectives  
•
Understand and be able to weigh in a clinical setting the risks and potential benefits of changing ARV therapy in a patient with an HIV RNA <50 copies/mL
•
Understand and be able to discuss the differences between various ARV agents and regimens regarding adverse events, including short and long-term tolerability issues, morphologic and metabolic disturbances, and cardiovascular risk
•
Describe clinical strategies to minimize ARV risks while maximizing the chance for long-term virologic suppression
•

Share best practice information and data through interactions with leading clinicians


Intended Audience
This activity is intended for physicians, physicians' assistants, and advanced practice nurses and other healthcare professionals involved in the treatment and management of patients with HIV infection. There are no prerequisites.
Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Presented By: